Randomised, double-blind, parallel-group, placebo-controlled, duloxetine referenced, dose-finding study of Lu AA24530 in Major Depressive Disorder

H. Lundbeck a/s0 个研究点目标入组 625 人开始时间: 2007年10月17日最近更新: 2012年5月1日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: H. Lundbeck a/s
入组人数: 625

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•The patient is able to read and understand the Patient Information Sheet.
•The patient has signed the Informed Consent Form.
•The patient has a Major Depressive Episode (MDE), diagnosed according to DSM-IV-TR criteria (classification code 296.xx) and confirmed according to the Mini-International Neuropsychiatric Interview (MINI) .
•The patient is a man or a woman, aged between 18 and 65 years (extremes included).
•The patient has a Major Depressive Episode that has lasted at least 3 months.
•The patient has a MADRS of total score = 26.
•The patient is able to swallow capsules.
•The patient, if female, must: agree not to try to become pregnant during the study, AND use adequate contraception (adequate contraception is defined as oral/systemic contraception, intrauterine device, diaphragm in combination with spermicide, or condom for male partner in combination with spermicide), OR have had her last natural menstruation at least 24 months prior to Baseline, OR have been surgically sterilised prior to Baseline, OR have had a hysterectomy prior to Baseline, OR not be sexually active.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•The patient has one or more of the following conditions: Any current psychiatric disorder established as the principal diagnosis other than MDD as defined in the DSM-IV-TR and assessed with the Mini-International Neuropsychiatric Interview (MINI), current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR, any substance use disorder (except nicotine) within the previous 6 months as defined in the DSM-IV-TR, presence or history of a clinically significant neurological disorder, any axis II disorder that might compromise the study.
•The patient is at significant risk of suicide either corroborated by MINI item A3g, a score =5 on item 10 on the MADRS (Iten No 10), a score of =3 on item 3 of the HAM-D-17 with MES (Iten No 3), or according to investigator’s opinion.
•The patient has a Major Depressive Episode that has been unresponsive to two adequate courses of antidepressant treatment of each at least 6 weeks duration.
•The patient has a history of lack of response to previous treatment with duloxetine.
•The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to duloxetine.
•The patient has received electroconvulsive therapy within 6 months prior to Baseline.
•The patient used/uses disallowed recent or concomitant medication (specified in Appendix II) or it is anticipated that the patient will require treatment with at least one of the disallowed concomitant medications during the study.
•The patient is currently receiving formal cognitive or behavioural therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
•The patient has a clinically significant unstable illness, for example, hepatic or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance.The patient has increased intra-ocular pressure or is at risk of acute narrow-angleglaucoma.The patient has a chronic liver disease.
•The patient has abnormal vital signs judged by the investigator to be indicative of significant illness.
•The patient has a history of seizures.
•The patient has a history of renal illness or damage or decreased renal function.
•The patient has one or more laboratory values outside the normal range, based on the blood samples taken at the Screening Visit, that are considered by the investigator to be indicative of significant illness.
•The patient has a thyroid-stimulating hormone (TSH) out of normal range
•The patient has an abnormal ECG judged by the investigator to be indicative of significant illness.
•The patient has a QTc above 450 ms.
•The patient has a history of hypokalaemia.
•The patient has a family history of Long QT Syndrome.
•The patient has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
•The patient has been treated with any investigational medicinal product within 30 days or 5 half lives (whichever is longer) prior to Baseline.
•The patient has a positive urine drug screen.
•The patient is pregnant or breast-feeding.
•The patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
•The patient is a member of the site person

研究者

发起方

H. Lundbeck a/s

相似试验

进行中（未招募）

不适用

Randomised, double-blind, parallel-group, placebo-controlled, and active referenced study of Lu AA34893 to evaluate the efficacy and safety of three doses Lu AA34893 and quetiapine versus placebo in the treatment of depression in patients with Bipolar I or II Disorder

EUCTR2007-002551-17-GBH. Lundbeck a/s600

进行中（未招募）

1 期

EUCTR2007-002551-17-DEH. Lundbeck a/s600

进行中（未招募）

1 期

Randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed dose study comparing the efficacy and safety of Lu AA21004 in acute treatment of major depressive disorder in elderly patients - Not applicable

EUCTR2008-002901-38-FIH. Lundbeck A/S450

进行中（未招募）

1 期

Study of Lu AE58054 in Patients With Mild-moderate Alzheimer's Disease Treated With DonepezilAlzheimer?s diseaseMedDRA version: 16.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852

EUCTR2012-004763-45-ESH. Lundbeck A/S930

进行中（未招募）

不适用

Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose comparison study of escitalopram in combination with two fixed doses of gaboxadol to escitalopram in Major Depressive DisorderMedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSMajor Depressive Disorder

EUCTR2008-000506-36-ATH. Lundbeck A/S500